A Study of Ganciclovir in the Treatment of Cytomegalovirus of the Eyes

Exclusion Criteria

• •Co-existing Condition:
• •Patients with the following symptoms or conditions are excluded:
• •Evidence of retinal vascular or related infectious disease or other retinal lesions that would interfere with the ability to detect responses to therapy or progression.
• •Corneal, lens, or vitreous opacification precluding funduscopic exam.
• •Clinically significant pulmonary or neurologic impairment other than seizure disorder or CNS mass lesion.
• •Inability to obtain temporary IV access.
• •Requirement for permanent catheters for IV ganciclovir administration.
• •Uncontrolled diarrhea or nausea preventing ingestion of medicine.
• •Known hypersensitivity to IV or oral ganciclovir.
• •Concurrent Medication:
• •Excluded:
• •Immunomodulators.
• •Biologic response modifiers.
• •Interferon.
• •Related investigational agents.
• •CMV prophylaxis.
• •Systemic acyclovir.
• •Any nephrotoxic agent.
• •Any concomitant therapy that would prohibit use of ganciclovir.
• •Prior Medication:
• •Excluded:
• •Prior treatment for CMV retinitis.
• •More than 4 months of prior ganciclovir or foscarnet, or within 4 weeks prior to study entry.